^
    Back
    Association details:
    Biomarker:PD-1 overexpression + CD8 positive
    Cancer:Non Small Cell Lung Cancer
    Drug Class:PD-L1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2020
    Title:

    4476 / 15 - PD-1 and TIGIT co-expression identifies a circulating CD8 T cell population predictive of response to anti-PD-1 therapy in melanoma and Merkel-cell carcinoma patients

    Published date:
    05/27/2020
    Excerpt:
    A population of PD-1high CD8 TILs was consequently described as predictive of PD-1 blockade in NSCLC.